Artemisinin-based antimalarials, such as artesunate (ART), alone or in combination, are the mainstay of the therapy against malaria caused by Plasmodium falciparum. However, the emergence and spread of artemisinin resistance threatens the future success of its global malaria eradication.
| INTRODUCTION
After the emergence of chloroquine-resistant Plasmodium falciparum in South East Asia and South America and their rapid dissemination across Africa in the 1980s Trape, 2001 ), artemisinin and its derivatives, such as artesunate (ART) or artemether, have been the treatment of choice (McIntosh & Olliaro, 2000) .
Artemisinin derivatives have a short half-life (Benakis, Paris, Loutan, Plessas, & Plessas, 1997) , and thus inadequate dose regimens lead to recrudescence. Therefore, this has led to the implementation of artemisinin-based combination therapy (ACT), where artemisinin derivatives are used in combination with long-acting partner drug for uncomplicated P. falciparum. The use of artesunate monotherapy is only applicable to treat severe malaria (World Health Organization, 2006) . Unfortunately, the efficacy of ACT has been threatened by the emergence and spread of artemisinin-resistant P. falciparum in western Cambodia (Noedl et al., 2008) , western Thailand (Phyo et al., 2012) , southern Burma (Kyaw et al., 2013) , and southern Vietnam (Hien et al., 2012) . Artemisinin resistance is generally characterised by a delay in parasite clearance after drug monotherapy, reflecting a partial reduction in parasite susceptibility, with efficacy restored by a substantially increased dose (Hastings & Watkins, 2006) .
Artemisinin resistance is thought to result from multiple factors such as the parasite genetic make-up, biological characteristics such as dormancy (Teuscher et al., 2010) , host factors (pharmacokinetic/ pharmacodynamics and immunity) (Krishna & Kremsner, 2013) , and/ or reduced efficacy or resistance to the partner drug (Amaratunga et al., 2016) . Most of the pioneering work on ART resistance has focused on the contribution of parasite genetic make-up; Anderson et al. (2010) demonstrated that around 60% of parasite clearance rate was explained by parasite genetic difference. Later studies identified genes and markers associated with resistance (Cheeseman et al., 2012; Takala-Harrison et al., 2013) such as mutations in the K13-propeller genes that are now widely used as marker of artemisinin resistance (Ariey et al., 2014; Ashley et al., 2014) .
Although most studies on artemisinin resistance focus on the intrinsic susceptibility of the parasite, a significant proportion of drug failures (~40%) is thought to be attributed other factors. Of these, the host immune response is thought to be critical in parasite clearance rates, during and after artemisinin therapy (Ataide et al., 2017; LoperaMesa et al., 2013; Monatrakul et al., 2010) . As the precise contribution of host immunity to drug efficacy is difficult to assess in humans, it has remained poorly characterised. Experimental murine malaria models † Carla Claser and Zi Wei Chang contributed equally to this work.
are particularly useful in understanding the contribution of specific immune effectors against the malaria parasite. To dissect the role of the immune system components in parasite clearance during and after ART monotherapy and during a primary infection, we used Plasmodium yoelii YM parasites in mice deficient for immune cells or mediators, or treated with cell-depleting antibodies.
2 | RESULTS
| Artesunate inhibits the development of PyYM in vitro
To determine the drug sensitivity of PyYM, a short-term ex vivo maturation culture of PyYM was performed (Chang, Malleret, Russell, Renia, & Claser, 2016) , and various doses of ART (0.2-1500 ng/ml) were tested (Figure 1 ). We also identified that the 50% inhibitory concentration (IC 50 ) of ART for PyYM is 62.14 nM ( Figure S1A ), showing to be less susceptible to ART than Plasmodium berghei ANKA and P. falciparum, where in the same assay done independently, their IC 50 was 15.4 and 1.5 nM, respectively (Chang et al., 2016; Malmquist et al., 2015; Suwanarusk et al., 2015) .
| Acquired immunity determines the therapeutic outcome of ART treatment
Next, we tested if ART efficacy in vivo was solely due to the direct effect on the parasites or required the help of the immune system. First, we defined the dose of ART required to inhibit parasitemia and prevent recrudescence in infected mice. In preliminary experiments, a 3-day treatment of 30 mg/kg body weight of artesunate given i.p. was administered to C57BL/6 J and BALB/c mice. These two mouse strains were tested since PyYM infection outcome differs in these strains. PyYM is lethal in BALB/c and semi-lethal in C57BL/6, where most mice developed immunity and cleared their parasitemia after 2 weeks. PyYM-infected mice were treated on Day 6 postinfection when infection was patent in order to mimic the situation when infected patients are diagnosed and treated. As shown in Figure 2a ,b, this treatment reduced parasitemia but did not completely eliminate the parasites. Moreover, when the treatment was stopped, ring parasites were observed ( Figure S2 ) and the parasite resumed growth in both mouse strains. This was likely due to ART short half-life in vivo.
Indeed, we showed that plasma taken from mice injected with ART at different time post-injection inhibited the ex vivo maturation of PyYM only in the first 30-min post-injection ( Figure S1B ). In a following experiment, to obtain a radical cure, we extended the dose treatment to 10 days. This treatment cleared the parasite rapidly in BALB/c mice in 4 days to level undetectable by microscopy. However, when treatment was stopped, parasite infection recrudesced before complete elimination could be observed (Figure 2a) . The treatment was then extended to 15 days, which allowed for the rapid clearance of parasitemias in 4 days and no recrudescence was observed after treatment cessation in both mouse strains (Figure 2a ,b). Because we were able to clear the parasite rapidly and to have a complete elimination after the treatment, we thus implemented this 15 days of ART treatment in all following experiments.
Next, using Rag2 −/− mice, which do not possess T and B cells, we demonstrated that the 15-day treatment with ART strongly inhibited the exponential growth of PyYM but was unable to block completely the parasite multiplication ( Figure S3B ). Despite parasite inhibition slopes being identical to the wild type mice for the first 10-days post-treatment, the inhibition was stalled afterwards ( Figure 2c ). As soon as the treatment was stopped, parasitemia was resumed ( Figure   S3B ), and by Day 40, all mice have succumbed to infection (Table 1, Figure S4B ).
Using B cell KO mice, we showed that ART treatment was dispensable for parasite clearance (Figure 2c ). However, as soon as
Inhibition assay of PyYM schizont maturation after drug treatment. Representative flow cytometry gating of PyYM-infected C57BL/6 mice (n = 12) used to define the percentage of schizonts inhibited by artesunate (ART). The target gate representing schizont development is indicated on each plot. Underneath the plots are the corresponding Giemsa-stained thick smear collected from the same culture wells the treatment was ceased, mice developed uncontrollable parasitemia (Table 1 and Figure S3D ). tion. CD8+ T cell absence had no effect on drug treatment efficacy and did not led to recrudescence ( Figure S5B ). In addition, we ruled out the 
Note. NM = no mortality implication of the main pro-inflammatory cytokines TNFα and IFNγ, because their absence did not impair parasite clearance, as complete elimination of the parasite from the circulation was observed in mice deficient for each of these two mediators, even after ART treatment was ceased ( Figure S5D and S5F, respectively).
| Host adaptive immune response influences parasite virulence
Since in the absence of host adaptive immunity, ART was not able to eliminate PyYM parasites; we wonder if these parasites would have developed any resistance to the drug. We thus infected Rag2 −/− mice with PyYM, and after 15 days of treatment with ART, the surviving parasites were isolated. We first assessed, in vitro, the susceptibility of this parasite (referred as PyYM RAG ) to the drug to see whether it has been affected. Surprisingly, the IC 50 of PyYM RAG was 24.21 nM,
showing that the parasite was intrinsically more sensitive to drug than its wild type counterpart (IC 50 : 62.14 nM; Figure S1A ). Then we compared the course of infection of PyYM or PyYM RAG in C57BL/6 J mice.
As shown in Figure 4a , PyYM RAG had a lower peak parasitemia than PyYM in untreated animals. In ART-treated animals, the parasitemia was similar during the treatment period. However, PyYM RAG did recrudesce at a later time point after the treatment was stopped (Figure 4b ). Since the blood parasitemia was reduced in PyYM RAG -infected mice, we hypothesised that this parasite could be having a prolonged ring phase of development and, therefore, an altered development as shown for artemisinin-treated falciparum parasites (Hott et al., 2015) .
To do so, we monitored the ex vivo maturation of intra-erythrocytic stage of PyYM and PyYM RAG parasite during 24 hr using a synchronous ring-stage culture. Comparison between both parasites showed no alteration in the intra-erythrocytic development in vitro (Figure 4 e,f). To test for intrinsic growth difference in vivo, Rag2 −/− mice were infected with PyYM or PyYM RAG . PyYM RAG was as lethal as the WT parasite (Figure 4g,h) , demonstrating that PyYM RAG has no growth deficit, but instead, the ART treatment has altered the parasite in a way that it became controllable by the adaptive immune system. Our data strongly suggests that antibodies and CD4 + T cells, which provide help to B cells for antibody production, are needed for the complete parasite elimination. However, the antibody response was only required in a later phase, since clearance (the initial decrease in FIGURE 4 Host immunity influences parasite virulence. PyYMluc-infected C57BL/6 mice were treated for 15 days with 30 mg/kg body weight of ART twice daily. Parasitemia of PyYM-or PyYM RAG -infected and untreated C57BL/6 (a) and BALB/c (c), and treated twice daily with ART (b,c). Parasitemia (%) values are expressed in log and as mean ± SD of 5 mice per group. ****p < .0001, unpaired t-test test (a); ****p < .0001, ordinary one-way ANOVA followed by Bonferroni's multiple comparisons test (c). (d) Survival of PyYM-or PyYM RAG -infected BALB/c, **p < .01, log-rank (Mantel-Cox test). Intra-erythrocytic parasite development monitored over 24 hr for PyYM (e) and PyYM RAG (f). Parasitemia (g) and survival (h) of PyYM-or PyYM RAG -infected Rag2 −/− mice parasitemia) of parasite in ART treated RAG-or B-deficient mice was similar to that of ART-treated WT mice. Treatment was started at we cannot ascertain whether these forms were dormant parasites or residual normal parasites that have escaped the destruction. Therefore, further studies will have to be performed to answer this question.
Further characterisation of recrudescent parasites, obtained from infected Rag2 −/− immunodeficient mice, showed that they were still susceptible to ART, even more so than WT parasites ( Figure S1A ). However, they did not show alteration in their growth phenotype in vivo when injected into RAG mice ( Figure 4F ) or in vitro, as it has been recently demonstrated for ART-resistant lines of P. falciparum (Hott et al., 2015) . On the other hand, when injected in immunocompetent BALB/c mice, PyYM RAG show a non-lethal phenotype compared to the WT parental line, which is lethal. This demonstrates that ART treatment has a profound effect on the parasite and that treatment alters the parasites in a way that allows recognition and elimination by the immune system. It is possible that ART treatment either favour the occurrence of genetic mutations or induce transcriptional changes in the parasite leading to differential expression of antigens. In both scenarios, these modifications will induce a protective antibody response against these antigens. Further studies are currently ongoing to uncover the modifications induced by ART treatment on the parasite and the infected red blood cell, which may lead to the discovery of new vaccine targets.
Lastly, it is important to consider the applicability of the murine model data in this study to the treatment of human P. falciparum infections with ART. In our experiments, we infected and treated naïve mice.
These mice do not have pre-existing immunity against the parasite, and thus, we assessed whether a developing immunity was necessary for the efficacy of ART. So far, all studies done in humans have assessed the effect of a pre-existing acquired immunity on clearance and elimination against P. falciparum. Lopera-Mesa et al (Lopera-Mesa et al., 2013) reported that clearance was age-dependent in Malian children. Since these children are constantly exposed to P. falciparum parasites, they have built overtime, both antibody and T cell responses against the parasite. More recently, it was reported that, in area of low-immunity anti-P. falciparum antibody titers were positively associated with faster parasite clearance rate, having a better effect on slow clearing kelch13 mutant parasites (Ataide et al., 2017) . Thus, it is more likely that in individuals with pre-existing immunity, immune memory plays a role in the early clearance and elimination of the parasite, as we have previously reported (Goh et al., 2016) . However, it still remains to be seen if clearance and parasite elimination occur faster after ART-treatment in immune mice during a secondary infection.
One important difference between the human and mouse parasite is that the IC 50 of ART against PyYM is 60 times higher than those in P. falciparum. Thus, explaining the lower efficacy of ART in vivo, where it takes 10-15 days to fully eliminate parasites compared to 3-7 days in humans (White, 2011 ; Table 1 ). Furthermore, the dose used in humans to treat uncomplicated P. falciparum ) is 10 times less than those in mice (2.4 mg/kg i.v. or i.m.). We ruled out the possibility of shorter half-life in vivo of ART in mice compared to humans since they were similar (~1 hr) (de Vries & Dien, 1996) .
Despite the above differences, we observed that the parasite clearing time during ART treatment was similar,~4 days for the two species (Figure 2c ; Dondorp et al., 2011) . In addition, it is well known that a 5-day ART monotherapy in humans leads frequently to recrudescence and that extending from 5 to 10 days has been shown to reduce treatment failure (Ittarat et al., 2003; Thanh et al., 2010) . This was also true in our mouse model. Our data suggest that complete parasite elimination results from the development protective antibodies able to eliminate residual parasites. We propose that a similar mechanisms may operate in humans infected with P. falciparum and treated with ART.
In conclusion, we show that the adaptive immune system plays an essential role in ART efficacy, opening the way to understanding the contribution of the immune system to artemisinin resistance. 
| Parasite and infection
For the experiments, we used transgenic P. yoelii YM expressing luciferase (PyYMluc) kindly provided by Dr. Kami Kim (Mwakingwe et al., 2009 Mwakingwe et al., 2009) . Parasitemia was monitored daily by flow cytometry starting from Day 3 till Day 12, and afterwards every other day till Day 60 or death of the last mouse. The protocol was followed as previously described (Malleret et al., 2011) .
| Drug treatment
Mice were treated with ART (Guilin No2 Pharmaceutical Factory, China) at Day 6 postinfection (p.i.) for 15 days. ART was prepared by dissolving 60 mg of powder in 30 ml of 0.9% NaCl to give a solution of 2 mg/ml. The solution was warmed at 37°C and then filtered with 0.22 μm filter. Mice were injected intraperitoneally (i.p) with 300 μl (30 mg/kg body weight) twice a day (morning and afternoon).
| In vivo antibody-mediated leukocyte subpopulation depletion
Purified rat IgG2a anti-mouse CD4 (clone GK1.5; BioXCell) mAbs was 
| Short-term in vitro culture
Mice with 1-2% parasitemia were anaesthetised in oxygen-rich induction chamber with 2% isoflurane, and 0.5 ml of blood was collected through retro-orbital puncture. Leukocytes were removed from heparinized infected blood samples using NFW (Tao, Xia, Cao, & Gao, 2011) and were washed twice in phosphate-buffered saline (PBS) solution. Following a protocol adapted from (Miao & Cui, 2011) , early stages parasites were enriched using 65% Percoll. The pellet containing rings and uninfected red blood cells were washed twice using complete RPMI medium (supplemented with 20% FBS and 1% penicillin/streptomycin).
| (i) IC 50
This pellet underwent to two rounds of dilutions. The first one was done with uninfected red blood cell to reach a final parasitemia of 1% followed by another one using complete RPMI medium to make 2% of haematocrit. After which, 100 μl of this diluted pellet was added to each well of a 96-well microtiter plate dosed with 0.2-1,500 ng/ml of ART (Sigma-Aldrich). Plates were next incubated in an atmosphere containing 5% CO2 at 37°C, until ≥50% of the ring stage parasites had matured to schizonts (20 to 22 hr). For each experiment, a negative control from uninfected blood and positive control from infected red blood cells was tested to confirm schizonts' maturation.
| (ii) Intra-erythrocytic development
Samples of cultures were collected every 3 hr up to 24 hr postincubation.
For both (i) and (ii), 80 μl of culture were used to do Giemsastained thin and thick smear. The remaining 20 μl of culture were collected and mixed with 80 μl of PBS to carry out flow cytometry. The mixture is stained with 8 um Hoechst 33342 (Sigma-Aldrich Pte Ltd, Singapore) and 5 μg/ml dihydro-ethidium. Diluted blood samples were incubated for 30 min at 37°C in the dark. After the incubation, 400 ml of cold PBS was added. 1 × 10 6 cells were acquired using LSR II flow cytometer (Becton Dickinson) with the UV laser. The data were analysed using FlowJo (Tree Star) software and for (i) normalised against the control well without anti-malarial drug; (ii) percentages of rings, trophozoites, and schizonts were determined. Graphs were plotted using GraphPad Prism 6.
| Parasite clearance time
The parasite clearance time (or parasite clearance ratio) was calculated fitting the slope of the linear decline in the average parasitemia over time (natural log scale) during the period of ART treatment (Stepniewska et al., 2010) . There were infections with lag in the clearance, during which the average parasitemia continued to increase after ART treatment but declined later. Therefore, the slope was fitted from the day with decline rather than Day 6 postinfection for these cases (Flegg, Guerin, White, & Stepniewska, 2011) A linear model provided a good fit for our data (mean R 2 = 0.914667 ± 0.03447).
| Microscopy
The image from thin blood smears stained with Giemsa was captured by using Nikon Eclipse TS100 microscope with 100× magnification, equipped with Nikon camera Digital Sight DS-5Mc and NIS-Elements F imaging software.
| Statistical analysis
Difference in survival was assessed with the log-rank Kaplan-Meier test. Parasitemia and intracellular staining results were analysed parametrically, using unpaired t-test test for differences between two groups and one-way ANOVA with Bonferroni's post-test for multiple groups. The data were analysed using GraphPad Prism software (version 6.0) and taking p < .05 as the level of significance. 
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